Two clinical trials test immunomodulator to improve cancer immunotherapy

Cancer immunotherapy, and in particular the so-called checkpoint inhibitors, have improved the prognosis of several types of tumours. However, they are not effective in everyone. Two early-stage clinical trials have tested the addition of a type of immunomodulator to this therapy in patients with lung cancer and Hodgkin's lymphoma, with apparent good results. The results are published in the journal Science.  

20/06/2024 - 20:00 CEST
 
Expert reactions

Joaquín Martínez López - dos ensayos inmuno EN

Joaquín Martínez López (EN)

Head of the Haematology Department at Hospital 12 de Octubre

Science Media Centre Spain

The studies are very interesting from a preclinical point of view and of great translational value for the future. The methodology used is very novel. However, the clinical part is still weak due to the small number of patients included. 

It is a further demonstration that boosting the action of T lymphocytes increases the response to immunotherapy treatments against cancer.

The author has not responded to our request to declare conflicts of interest
EN
Publications
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
  • Research article
  • Peer reviewed
Journal
Science
Publication date
Authors

Mathew et al.

Study types:
  • Research article
  • Peer reviewed
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
  • Research article
  • Peer reviewed
Journal
Science
Publication date
Authors

Zak et al.

Study types:
  • Research article
  • Peer reviewed
The 5Ws +1
Publish it
FAQ
Contact